DOCSLIB.ORG

Clinical Trial Landscape and Phase 3 COVID-19 Vaccine Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Trial Landscape and Phase 3 COVID-19 Vaccine Update Clinical Trial Landscape and Phase 3 COVID-19 Vaccine Update Emily Coates, PhD Larisa Strom, Colorado School of Public Health Colorado Vaccine Equity Taskforce: Training on COVID-19 Vaccine Development November 20, 2020 Outline • Overview of U.S. federal health agencies • Clinical trial phases and regulations of vaccines • Vaccine safety and efficacy standards • U.S. government’s COVID-19 vaccine strategy • Phase 3 COVID-19 vaccine candidates in the U.S. • Strategies for vaccine distribution following FDA Emergency Use Authorization (EUA)/Biological License Application Approval Overview of the Department of Health and Human Services (HHS) • Founded in 1953 as a department within the Department of Health, Education, and Welfare; reorganized as single entity in 1980 • Mission statement: “to enhance the health and well-being of all Americans, by providing for effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services” • Comprised of 11 operating divisions, including the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) • HHS total budget authority for fiscal year 2020: 1,292,523 (in millions) • FDA: $5,900; CDC: $6,767; NIH: $41,680 • Workforce: 84,505 employees (2018) • Mission: “to protect the public health by ensuring the safety, efficacy, and security of human Food and Drug and veterinary drugs, biological Administration products, and medical devices” • Regulates vaccine clinical trials, (FDA) licenses vaccines, and monitors vaccine safety after licensure • Workforce: 18,555 employees • Mission: “to protect America from health, safety and security threats, Centers for Disease both foreign and in the U.S.” • Promotes immunization at the Control and country, regional, and global Prevention (CDC) levels by providing evidence-based strategies to control and eliminate vaccine-preventable diseases • Workforce: 10,796 employees • Mission: “to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability” National Institutes • Comprised of 27 institutes including the National of Health (NIH) Institute of Allergy and Infectious Diseases (NIAID) • Within NIAID, the Vaccine Research Center (VRC) “conducts research that facilitates the development of effective vaccines for human disease” • Workforce: 18,668 employees Other Divisions within HHS • Administration for Children and Families (ACF) • Administration for Community Living (ACL) • Agency for Healthcare Research and Quality (AHRQ) • Agency for Toxic Substances and Disease Registry (ATSDR) • Centers for Medicare & Medicaid Services (CMS) • Health Resources and Services Administration (HRSA) • Indian Health Service (IHS) • Substance Abuse and Mental Health Services Administration (SAMHSA) Outline • Overview of U.S. federal health agencies • Clinical trial phases and regulations of vaccines • Vaccine safety and efficacy standards • U.S. government’s COVID-19 vaccine strategy • Phase 3 COVID-19 vaccine candidates in the U.S. • Strategies for vaccine distribution following EUA Source: Centers for Disease Control and Prevention Clinical Trial Operations and Recruitment Questions How does NIH recruit for clinical trials? • Advertising in public places such as transit, radio, newspapers, bulletins • How are communities of color engaged/selected for VRC trials? • Advertisements on radio stations catering to urban or Spanish-speaking populations • Informed consent documents in Spanish to facilitate trial participation in that underrepresented ethnic group • Community outreach to college campuses, including community colleges Is there a minimum threshold of minority population inclusion that must be met in a clinical trial? • While there is no minimum threshold, the FDA strongly encourages that participants from diverse populations are included in all phases of vaccine development to ensure that vaccines are safe and effective in all affected populations • Vaccine safety and efficacy assessments, particularly in late phase clinical trials, should include an adequate representation of populations most impacted by COVID-19, specifically racial and ethnic minority groups Are community advisory boards a requirement for clinical trials? • Although not required, community advisory boards can be utilized to provide feedback or raise concerns during the protocol development stage • Institutional Review Boards (IRBs) are required and designated under FDA regulations to review and monitor biomedical research involving human subjects • Human subjects research: research that uses, studies, or analyzes information or biospecimens through intervention or interaction with subject; or research that uses, studies, analyzes, or generates identifiable private information or biospecimens • IRBs have authority to approve, require modifications to, or disapprove research FDA Emergency Use Authorizations (EUA) What is an FDA Emergency Use Authorization? • EUA allows the use of unapproved medical products to diagnose, treat, or prevent serious or life-threatening diseases in response to a declared public health emergency for which there are no adequate, approved, and available treatments • Introduced in 2004 as a measure against weapons of mass destruction • Criteria for issuing an EUA: • The known and potential benefits of the product outweigh the product’s known and potential risks • Sufficient data on product’s safety profile • Proof of worthwhile efficacy • Cannot be granted outside of a declared emergency • EUAs have previously been granted to products for anthrax, Ebola, Enterovirus, Zika, H1N1 influenza, MERS • EUA has only been granted for one vaccine, Anthrax Vaccine Adsorbed (AVA) in 2005, for individuals ages 18-65 at heightened risk of anthrax exposure Why now? FDA October 2020 Emergency Use Authorization for Vaccines to Prevent COVID-19: • FDA recommends EUA if data from phase 3 studies supports a positive benefit-risk assessment • Efficacy standard for approving EUA for COVID-19 vaccine: >=50% disease reduction in treatment vs placebo groups • A median of 2 months of safety follow-up data is required before companies can apply for EUA • Following Authorization: • Not subject to usual informed consent requirements, but recipients are provided a fact sheet detailing the product, its potential risks and benefits, and have the option to refuse the product • To minimize risk of EUA interfering with long-term safety and efficacy assessments, it is essential that data is still gathered on the vaccine even after the EUA Outline • Overview of U.S. federal health agencies • Clinical trial phases and regulations of vaccines • Vaccine safety and efficacy standards • U.S. government’s COVID-19 vaccine strategy • Phase 3 COVID-19 vaccine candidates in the U.S. • Strategies for vaccine distribution following EUA What criteria are used to deem a vaccine “safe”? • Pre-clinical studies to assess safety • In vitro and in vivo testing help define immunogenicity and safety profile • Animal models help identify vaccine-related safety risks and assist in selecting an appropriate dose, regimen, and administration route • Clinical trials • Safety is monitored for a 2-month median follow-up after full vaccination regimen to allow for detecting any potential AEs • FDA usually requires 6 or more months of safety follow-up for serious or other medically attended AEs before approving the licensure of a vaccine • Data and Safety Monitoring Boards (DSMBs) • Independent group of experts who oversee clinical trials and whose roles include: • Periodical review and evaluation of participant safety, study conduct and progress, and efficacy (if necessary) • Ability to make recommendations regarding trial continuation, modification, or termination When is a DSMB required? • A DSMB is required for: • All Phase 3 trials* • High-risk Phase 2 trials • Multi-site and randomized Phase 2 trials* • May be required for Phase 1 or 2 trials if trial is blinded, first-in-man, includes high-risk populations, or involves high-risk interventions • A DSMB is not generally required (but may still be recommended) for: • Single-center, open-label Phase 1 and 2 trials • Multi-site, high-risk Phase 1 trials with clear guidelines and criteria for halting the trial if unexpected side effects occur *Excludes certain low-risk nutritional or behavioral studies where participants should only experience mild side effects Assessing Long-term Safety after Licensure • As with all licensed vaccines, the vaccine’s safety profile will continue to be monitored post-licensure in order to facilitate detecting any rare AEs in the general population and populations underrepresented in pre-licensure trials • Phase IV trials may be conducted to continue assessing vaccine safety profile after licensure • Pharmacovigilance plan for COVID-19: 24-month post-licensure monitoring between CDC and FDA to determine vaccine’s performance in real-life scenarios to monitor efficacy and rare adverse events not found in pre-licensure trials • Post-licensure monitoring systems: • Vaccine Adverse Event Reporting System (VAERS) • Vaccine Safety Datalink (VSD) • Post-Licensure Rapid Immunization Safety Monitoring (PRISM) • Clinical Immunization Safety Assessment Project (CISA) Vaccine Adverse Event Reporting System (VAERS) • Co-managed by CDC and FDA • National early warning system that detects unexpected
Load more

Recommended publications
  • Version 12.0, 01 Jun 2018 ANNEX I SUMMARY of PRODUCT
    BioThrax® (Anthrax Vaccine Adsorbed) 1.3.1 Summary of Product Characteristics, Labelling and Package Leaflet Version 12.0, 01 Jun 2018 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET Emergent BioSolutions, Inc. Confidential and Proprietary Page 1 of 25 BioThrax® (Anthrax Vaccine Adsorbed) 1.3.1 Summary of Product Characteristics, Labelling and Package Leaflet SUMMARY OF PRODUCT CHARACTERISTICS Emergent BioSolutions, Inc. Confidential and Proprietary Page 2 of 25 BioThrax® (Anthrax Vaccine Adsorbed) 1.3.1 Summary of Product Characteristics, Labelling and Package Leaflet This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See Section 4.8 for how to report adverse reactions 1 NAME OF THE MEDICINAL PRODUCT BioThrax1 suspension for injection. Anthrax Vaccine Adsorbed (purified cell-free filtrate) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 mL) contains: Anthrax antigen filtrate: 50 micrograms (50 mcg) a, b For a full list of excipients, see Section 6.1. a Produced from cell-free filtrates of an avirulent strain of Bacillus anthracis b Adsorbed on aluminium hydroxide, hydrated (0.6 mg Al3+) 3 PHARMACEUTICAL FORM Suspension for injection. Sterile, milky-white liquid suspension, when mixed. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications BioThrax is indicated for the prevention of disease caused by Bacillus anthracis, in adults at risk of exposure. BioThrax should be used in accordance with official recommendations, where available. 4.2 Posology and method of administration Posology: Primary Immunisation: 3-doses each of 0.5 mL, given at 0, 1 and 6 months.
    [Show full text]
  • The Effect of Raxibacumab on the Immunogenicity of Anthrax Vaccine Adsorbed: a Phase
    The effect of raxibacumab on the immunogenicity of anthrax vaccine adsorbed: a Phase IV, randomised, open-label, parallel-group, non-inferiority study Nancy Skoura, PhD1, Jie Wang-Jairaj, MD2, Oscar Della Pasqua MD2, Vijayalakshmi Chandrasekaran, MS1, Julia Billiard, PhD1, Anne Yeakey, MD3, William Smith, MD4, Helen Steel, MD2, Lionel K Tan, FRCP2 1GlaxoSmithKline, Inc. Collegeville, PA, USA 2GlaxoSmithKline. Stockley Park West, Middlesex, UK 3GlaxoSmithKline, Inc. Rockville, MD, USA 4AMR, at University of TN Medical Center, Knoxville, TN; New Orleans Center for Clinical Research (NOCCR), USA Author for Correspondence: Dr Lionel K Tan GlaxoSmithKline Stockley Park West 1–3 Ironbridge Road Uxbridge Middlesex UB11 1BT UK Email: [email protected] Tel: +44 (0)7341 079 683 1 Abstract: 340/350 Body text: 4321/4500 words including Research in Context Table/Figures: 2/4 References: 30 2 Abstract Background Raxibacumab is a monoclonal antibody (Ab) which binds protective antigen (PA) of Bacillus anthracis and is approved for treatment and post-exposure prophylaxis (PEP) of inhalational anthrax. Anthrax vaccine adsorbed (AVA), for anthrax prophylaxis, consists primarily of adsorbed PA. This post-approval study evaluated the effect of raxibacumab on immunogenicity of AVA. Methods In this open-label, parallel-group, non-inferiority study in three centres in the USA, healthy volunteers (aged 18–65 years) with no evidence of PA pre-exposure were randomised 1:1 to receive either subcutaneous 0·5 mL AVA on Days 1, 15, and 29 or raxibacumab intravenous infusion (40 mg/kg) immediately before AVA on Day 1, followed by AVA only on Days 15 and 29.
    [Show full text]
  • Whether Section 564 of the Food, Drug, and Cosmetic Act Prohibits Entities from Requiring the Use of a Vaccine Subject to an Emergency Use Authorization
    (Slip Opinion) Whether Section 564 of the Food, Drug, and Cosmetic Act Prohibits Entities from Requiring the Use of a Vaccine Subject to an Emergency Use Authorization Section 564(e)(1)(A)(ii)(III) of the Food, Drug, and Cosmetic Act concerns only the provision of information to potential vaccine recipients and does not prohibit public or private entities from imposing vaccination requirements for a vaccine that is subject to an emergency use authorization. July 6, 2021 MEMORANDUM OPINION FOR THE DEPUTY COUNSEL TO THE PRESIDENT Section 564 of the Food, Drug, and Cosmetic Act (“FDCA”), 21 U.S.C. § 360bbb-3,1 authorizes the Food and Drug Administration (“FDA”) to issue an “emergency use authorization” (“EUA”) for a medical product, such as a vaccine, under certain emergency circumstances. This authoriza- tion permits the product to be introduced into interstate commerce and administered to individuals even when FDA has not approved the product for more general distribution pursuant to its standard review process. Section 564 directs FDA—“to the extent practicable” given the emergen- cy circumstances and “as the [agency] finds necessary or appropriate to protect the public health”—to impose “[a]ppropriate” conditions on each EUA. FDCA § 564(e)(1)(A). Some of these conditions are designed to ensure that recipients of the product “are informed” of certain things, including “the option to accept or refuse administration of the product.” Id. § 564(e)(1)(A)(ii)(III). Since December 2020, FDA has granted EUAs for three vaccines to prevent coronavirus disease 2019 (“COVID-19”). In each of these author- izations, FDA imposed the “option to accept or refuse” condition by requiring the distribution to potential vaccine recipients of a Fact Sheet that states: “It is your choice to receive or not receive [the vaccine].
    [Show full text]
  • Considerations for Anthrax Vaccine Adsorbed (Ava) Post- Exposure Prioritization
    2013 The Centers for Disease Control and Prevention FINAL CONSIDERATIONS FOR ANTHRAX VACCINE ADSORBED (AVA) POST- EXPOSURE PRIORITIZATION FINAL DISCLAIMER: This document considers prioritization of Anthrax Vaccine Adsorbed (AVA) in a post-event setting. This document does not include implementation considerations for post-event vaccination. This document does not include policy or implementation considerations for pre-event vaccination. This document does not include policy considerations for reserving vaccine in a post-event setting (e.g., holding back vaccine because of high risk of subsequent event). This document does not address vaccination for long-term exposure risks to Bacillus anthracis spores (> 6 months). The principles in this document apply regardless of the number of doses available. TABLE OF CONTENTS PRELUDE ...................................................................................................................................................... 1 1. BACKGROUND ON ANTHRAX AND AVA ................................................................................................ 2 1.1 Information about Anthrax Vaccine Adsorbed (AVA) .................................................................. 2 1.2 Anthrax as a Public Health Concern ............................................................................................ 3 2. AVA PRIORITIZATION GUIDANCE BACKGROUND AND METHODS ........................................................... 4 3. DEFINITIONS AND MAJOR CONCEPTS..................................................................................................
    [Show full text]
  • COVID 19 Review
    COVID 19 Review Monografia n. 5 Covid19 e i vaccini: a che punto siamo. A cura di Giorgio Banchieri, Antonio Giulio De Belvis, Maurizio Dal Maso, Stefania Mariantoni, Mario Ronchetti, Andrea Vannucci. Review realizzata in collaborazione con : 1 Nota redazionale. I materiali (articoli e dati) vengono selezionati da fonti accreditate: . Per gli articoli: The Lancet, British Medicine Journal, The New York Times, Science, Nature, Oxford Review, Cambridge Review, Quotidiano Sanità, Il Corriere della Sera, Il Sole 24Ore Sanità, La Repubblica e altri; Per le Istituzioni: . WH0/OMS, UE Centri di Prevenzione; OCDE, ONU, Protezione Civile, ISTAT, INAIL, Ministero Salute, ISS, AGENAS, CNR, Regioni, ARS, ASL, AO, AOP, IRCCS, Centri Studi e ricerche nazionali e internazionali e altri; Per i dati: . WH0/OMS, UE Centri di Prevenzione; OCDE, ONU, Protezione Civile, ISTAT, INAIL, Ministero Salute, ISS, AGENAS, CNR, Regioni, ARS, ASL, AO, AOP, IRCCS, Centri Studi e ricerche nazionali e internazionali e altri; Criteri di selezione: I materiali sono scelti in base ai seguenti criteri: Materiali di analisi recenti; Fonti accreditate; Tematiche inerenti a COVID19; Procedure internazionali e nazionali; Studi e ricerche epidemiologici; Studi su procedure per operatori sanitari e sociali; Linee Guida internazionali, nazionali e regionali; Linee Guida di società scientifiche e professionali. Le traduzioni sono fatte in automatico con il software “google” per rapidità di fruizione. Ci scusiamo se le traduzioni non sono sempre adeguate, ma riteniamo più utile la
    [Show full text]
  • Vaccines Licensed for Use in the United States by the Food and Drug
    Vaccines Licensed for Use in the United States by the Food and Drug Administration (FDA) Cell Lines Used for Viral Vaccine Production Current FDA list accessed 4 January 2021 Use of Cell Lines for Vaccine Production Vaccine Product Name No fetal cells (linked to FDA vaccine page Vaccine Trade Name fetal cells including package insert) -- no cell lines - bacteria grow independently WI-38 Adenovirus Type 4 and Type 7 Vaccine, No Trade Name Live, Oral -- Anthrax Vaccine Adsorbed Biothrax -- BCG Live BCG Vaccine -- BCG Live TICE BCG -- Cholera Vaccine Live Oral Vaxchora Vero Dengue Tetravalent Vaccine, Live DENGVAXIA -- Diphtheria & Tetanus Toxoids Adsorbed No Trade Name -- Diphtheria & Tetanus Toxoids & Acellular Infanrix Pertussis Vaccine Adsorbed -- Diphtheria & Tetanus Toxoids & Acellular DAPTACEL Pertussis Vaccine Adsorbed Yeast (HepB) Diphtheria & Tetanus Toxoids & Acellular Vero (polio) Pertussis Vaccine Adsorbed, Hepatitis B Pediarix -- diphtheria, tetanus, (recombinant) and Inactivated Poliovirus pertussis Vaccine Combined Vero (polio) Diphtheria and Tetanus Toxoids and -- diphtheria, tetanus, Acellular Pertussis Adsorbed and Inactivated KINRIX pertussis Poliovirus Vaccine Vero (polio) Diphtheria and Tetanus Toxoids and -- diphtheria, tetanus, Acellular Pertussis Adsorbed and Inactivated Quadracel pertussis Poliovirus Vaccine Yeast (HepB) Diphtheria and Tetanus Toxoids and Vero (polio) Acellular Pertussis Adsorbed, Inactivated -- diphtheria, tetanus, Poliovirus, Haemophilus b Conjugate VAXELIS pertussis, haemophilus [Meningococcal
    [Show full text]
  • The Anthrax Vaccine Debate: a Medical Review for Commanders
    The Anthrax Vaccine Debate: A Medical Review For Commanders Colonel Richard A. Hersack, USAF US Air Force Counterproliferation Center 10 Future Warfare Series No. 10 THE ANTHRAX VACCINE DEBATE: A MEDICAL REVIEW FOR COMMANDERS by Richard A. Hersack, Col, USAF, MC, CFS The Counterproliferation Papers Future Warfare Series No. 10 USAF Counterproliferation Center Air War College Air University Maxwell Air Force Base, Alabama The Anthrax Vaccine Debate: A Medical Review for Commanders Richard A. Hersack, Col, USAF, MC, CFS April 2001 The Counterproliferation Papers Series was established by the USAF Counterproliferation Center to provide information and analysis to assist the understanding of the U.S. national security policy-makers and USAF officers to help them better prepare to counter the threat from weapons of mass destruction. Copies of No. 10 and previous papers in this series are available from the USAF Counterproliferation Center, 325 Chennault Circle, Maxwell AFB AL 36112-6427. The fax number is (334) 953- 7530; phone (334) 953-7538. Counterproliferation Paper No. 10 USAF Counterproliferation Center Air War College Air University Maxwell Air Force Base, Alabama 36112-6427 The internet address for the USAF Counterproliferation Center is: http://www.au.af.mil/au/awc/awcgate/awc-cps.htm Executive Summary There are two distinct yet related aspects to the debate over the safety and efficacy of the anthrax vaccine. - An assessment of the clinical safety and efficacy of the anthrax vaccine. - The policy level decision to vaccinate military personnel based on intelligence reports and assessments. - The policy decision to vaccinate is based on an assessment of relative risk.
    [Show full text]
  • Federal Register/Vol. 70, No. 242/Monday, December
    75180 Federal Register / Vol. 70, No. 242 / Monday, December 19, 2005 / Notices Control System, Medicare contractors DEPARTMENT OF HEALTH AND survey local welfare staff to gather in- and the Coordination of Benefit HUMAN SERVICES depth qualitative information on how Contractor, Common Working File, CMS workers interpret the policies and apply Regional Offices, an agency of a State Administration for Children and them in specific instances. The results government, Medicare beneficiaries and Families of this study should give the non-Medicare beneficiaries that have an Administration for Children and approved or denied WC Medicare Set- Proposed Information Collection Activity; Comment Request Families (ACF) a better understanding aside arrangement to cover future of possible outcomes of various sanction medical costs resulting from an injury Proposed Projects policies, which in turn will help ACF incurred while employed and the Social Title: Sanction Policies Task Order. design a research program to study the Security Administration. effect of sanctions. OMB No.: New Collection. SYSTEMS EXEMPTED FROM CERTAIN PROVISION Respondents: A maximum of 324 OF THE ACT: Description: This study is designed to determine how local welfare offices welfare staff in local welfare offices. None. implement sanction policies in the [FR Doc. E5–7486 Filed 12–16–05; 8:45 am] Temporary Assistance for Needy BILLING CODE 4120–03–P Families program. This study will ANNUAL BURDEN ESTIMATES Number of Average Number of responses burden Total burden Instrument respondents per respond- hours per re- hours ent sponse In-person Survey and Telephone Interviews ................................................... 324 1 .85 275 Estimated Total Annual Burden Dated: December 12, 2005. thereby determining if it may remain Hours: 275.
    [Show full text]
  • RNA-Based COVID-19 Vaccine Bnt162b2 Selected for a Pivotal Efficacy Study Edward E
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.17.20176651; this version posted August 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study Edward E. Walsh, MD1*, Robert Frenck, MD2*, Ann R. Falsey, MD1, Nicholas Kitchin, MD3a, Judith Absalon, MD3b, Alejandra Gurtman, MD3b, Stephen Lockhart, DM3a, Kathleen Neuzil, MD4, Mark J. Mulligan, MD5, Ruth Bailey, BSc3a, Kena A. Swanson, PhD3b, Ping Li, PhD3c, Kenneth Koury, PhD3b,Warren Kalina, PhD3b, David Cooper, PhD3b, Camila Fontes-Garfias, BSc6, Pei-Yong Shi, PhD6, zlem Türeci, MD7, Kristin R. Tompkins, BSc3b, Kirsten E. Lyke, MD4, Vanessa Raabe, MD5, Philip R. Dormitzer, MD3b, Kathrin U. Jansen, PhD3b, Uğur Şahin, MD7 and William C. Gruber, MD3b *Drs. Walsh and Frenck contributed equally to this article. 1University of Rochester and Rochester General Hospital, Rochester, NY; 2Cincinnati Children’s Hospital, Cincinnati, OH; 3Vaccine Research and Development, Pfizer Inc, aHurley, UK, bPearl River, NY, cCollegeville, PA; 4University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD; 5New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY; 6University of Texas Medical Branch, Galveston, TX; 7BioNTech, Mainz, Germany. Corresponding Author: Judith Absalon, MD, MPH, FIDSA Pfizer Inc 1401 North Middletown Road Pearl River, NY 10965 [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • CBER List of Licensed Biological Products With
    Center for Biologic Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date REFERENCE PRODUCT DATE OF LICENSURE DATE OF FIRST LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE(I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSMILAR (B) WITHDRAWN 125296 Adenovirus Type 4 and Type 7 Vaccine, Live, Oral 3/16/2011 Plasbumin-5; Plasbumin-20; Plasbumin-25; 101138 Albumin (Human) Albuked 10/21/1942 NA NA Buminate; Buminate 25%; Buminate 5%; 101452 Albumin (Human) Buminate 20%; Flexbumin 3/3/1954 NA NA 101993 Albumin (Human) 9/7/1979 NA NA 102366 Albumin (Human) AlbuRx 7/23/1976 NA NA 102478 Albumin (Human) Albutein 8/15/1978 NA NA 103352 Albumin (Human) 2/17/1995 NA NA Albuminar; Albuminar-5; Albuminar-20; 103955 Albumin (Human) Albuminar-25 5/17/1949 NA NA 125154 Albumin (Human) 10/17/2006 NA NA 125384 Albumin (Human) kedbumin 6/3/2011 125644 Albumin (Human)-kjda ALBUMINEX 6/19/2018 Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine 125400 Collagen GINTUIT 3/9/2012 103174 Alpha-1-Proteinase Inhibitor (Human) Prolastin; Prolastin-C 12/2/1987 NA NA 125039 Alpha-1-Proteinase Inhibitor (Human) Aralast; Aralast NP 12/23/2002 NA NA 125078 Alpha-1-Proteinase Inhibitor (Human) Zemaira 7/8/2003 NA NA 125325 Alpha-1-Proteinase Inhibitor (Human) Glassia 7/1/2010 103324 Animal Allergens, Standardized Cat Hair 7/11/1930 NA NA 103368 Animal Allergens, Standardized Cat Hair 3/22/1974 NA NA 103397 Animal
    [Show full text]
  • ACIP Meeting February 25-26 2009
    FINAL – February 20, 2009 MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Centers for Disease Control and Prevention 1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Atlanta, Georgia February 25-26, 2009 AGENDA ITEM PURPOSE PRESIDER/PRESENTER(s) Wednesday, February 25, 2009 8:00 Welcome & Introductions Dr. Dale Morse (Chair, ACIP) Dr. Larry Pickering (Executive Secretary, ACIP; CDC) 8:30 Anthrax Vaccine • BioThrax® (Anthrax Vaccine Adsorbed): reduced Information Dr. Robert Hopkins (Emergent dose/route change study – immunogenicity results BioSolutions) • Draft recommendation for route/schedule of Anthrax Information Dr. Jennifer Wright Vaccine Adsorbed (AVA) Discussion (CDC/CCID/NCIRD/DBD) Vote 8:55 Hepatitis Vaccines • Hepatitis A vaccination among contacts of Information Dr. Mark Sawyer (ACIP, WG Chair) internationally adopted children Discussion Dr. Sandra Chaves and Dr. Cindy Vote Weinbaum (CDC/CCID/NCHHSTP/DVH) 9:55 Break 10:25 Influenza Vaccines • Introduction Dr. Kathy Neuzil (ACIP, WG Chair) • Influenza surveillance update Information Dr. Anthony Fiore • Antiviral resistance Discussion (CDC/CCID/NCIRD/ID) • 2009 influenza vaccine recommendations Vote 11:25 Rabies Vaccine Information Dr. Paul Cieslak (ACIP, WG Chair) Discussion Dr. Charles Rupprecht (CDC/CCID/NCZVED/DVRD) 12:10 Update: Pertussis Vaccines Work Group Information Dr. Mark Sawyer (ACIP, WG Chair) Dr. Jennifer Liang (CDC/CCID/NCIRD/DBD) 12:15 Lunch 1:15 Pneumococcal Vaccines • Use of PPSV23 for prevention of pneumococcal Information Dr. Matthew Moore pneumonia during an influenza pandemic Discussion (CDC/CCID/NCIRD/DBD) • An economic analysis for use of PPSV23 for prevention Information Dr. Mark Messonnier of pneumococcal pneumonia during an influenza Discussion (CDC/CCID/NCIRD/ISD) pandemic • Update on PCV13 pediatric phase 3 trial results Information Dr.
    [Show full text]
  • Study Protocol
    BARDA BioThrax and AV7909 Protocol: BP-C-17001 Version 2.0 16 April 2018 CLINICAL STUDY PROTOCOL Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax®) without and with CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health BARDA Securing Anthrax Immunity For the Elderly (B-SAFE) BP-C-17001 Sponsor: Biomedical Advanced Research and Development Authority (BARDA) Sponsor Contact: Medical Monitor: Version of Protocol: 2.0 Date of Protocol: 16 April 2018 Previous Date and Version: 20 February 2018; Version 1.0 CONFIDENTIAL All financial and nonfinancial support for this study will be provided by BARDA. The concepts and information contained in this document or generated during the study are considered proprietary and may not be disclosed in whole or in part without the expressed, written consent of BARDA. The study will be conducted according to the Integrated Addendum to International Conference on Harmonisation (ICH) E6 (R1): Guideline for Good Clinical Practice (GCP) E6 (R2). 1 BARDA BioThrax and AV7909 Protocol: BP-C-17001 Version 2.0 16 April 2018 Investigator’s Agreement Study Title Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax®) without and with CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health Short Title BARDA Securing Anthrax Immunity For the Elderly (B-SAFE) Protocol Number BP-C-17001 Protocol Version Version 2.0 Protocol Date 16 April 2018 I have read and understood all sections of the above referenced protocol, the current package insert for BioThrax, and the investigator’s brochure for AV7909 Anthrax Vaccine.
    [Show full text]